Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

77P - A prognostic nomogram for the prediction of neuroblastoma

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Central Nervous System Malignancies

Presenters

Jian-Guo Zhou

Citation

Annals of Oncology (2019) 30 (suppl_9): ix182-ersion="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.9

Authors

J. Zhou, H. Ma

Author affiliations

  • Department Of Oncology, Zunyi Medical College Affiliated Hospital, 563000 - Zunyi City/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 77P

Background

Neuroblastoma (NBL) is the most common and aggressive cancer in infants, and there are no robust predictive nomograms for NBL. In this study, a database from the Therapeutically Applicable Research to Generate Effective Treatments was applied to develop and validate a prognostic nomogram for the prediction of individual 5-year overall survival (OS) probability in patients with NBL.

Methods

A total of 729 eligible NBL patients with their clinicopathological factors and biological characteristics from the database were assigned to either the training cohort (n = 511) or the validation cohort (n = 218). Independent predictors were identified by fitting the Cox model with lasso penalty and then were assembled into a nomogram to predict survival. The model was developed for predicting individual 5-year OS probability and was then internally and externally validated, calibrated and compared in each cohort.

Results

Four independent prognostic factors (International NBL Staging System stage, ploidy, histology and Children’s Oncology Group risk group) were discriminated and achieved favourable prediction efficacy following the lasso model. The prognostic nomogram incorporated those factors that performed well in the training and validation cohorts with OS (HR = 0.36, 95% CI: 0.27-0.48, P < 0.0 001; HR = 0.54, 95% CI: 0.34-0.86, P = 0.0 086; respectively) and recurrence-free survival (HR = 0.52, 95% CI: 0.40-0.67, P < 0.0 001; HR = 0.66, 95% CI: 0.44-0.99, P = 0.044; respectively).

Conclusions

The robust prognostic nomogram with four independent prognostic factors can accurately and diversely predict OS and recurrence-free survival in NBL patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.